Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Nilanjan Ghosh¹, Toby A Eyre², Jennifer R Brown³, Nicole Lamanna⁴, Beenish S Manzoor⁵, Catherine C Coombs⁶, Hande H Tuncer³, Chaitra Ujjani⁷, Lori A Leslie⁸, Lindsey E Roeker⁹, Matthew S Davids³, Joanna M Rhodes¹⁰, Alan P Skarbnik¹¹, Wendy Sinai⁵, Isabelle Fleury¹², Brian T Hill¹³, Nicolas Martinez-Calle¹⁴, Paul M Barr¹⁵, Dureshahwar Jawaid⁵, Nnadozie Emechebe⁵, Laurie Pearson¹⁶, Frederick Lansigan¹⁷, Yun Choi¹⁸, Christopher E Jensen¹⁹, Bita Fakhri²⁰, Deborah M Stephens¹⁹, Steven E Marx⁵, Stephen J Schuster²¹, Michael Coyle²², Irina Pivneva²³, Talissa Watson²³, Annie Guerin²³, Mazyar Shadman⁷

Affiliations

¹ Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, North Carolina, USA.
² Churchill Hospital, Oxford University, Oxford, UK.
³ Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
⁴ Columbia University, New York, New York, USA.
⁵ AbbVie Inc., North Chicago, Illinois, USA.
⁶ University of California Irvine, Irvine, California, USA.
⁷ Fred Hutchinson Cancer Research Center, Seattle, Washington State, USA.
⁸ John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, USA.
⁹ CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
¹⁰ Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
¹¹ Lymphoma and CLL Program, Novant Health Cancer Institute, Charlotte, North Carolina, USA.
¹² Hôpital Maisonneuve-Rosemont, University of Montreal, Canada.
¹³ Cleveland Clinic, Cleveland, Ohio, USA.
¹⁴ Nottingham University Hospitals, NHS Trust, Nottingham, UK.
¹⁵ Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.
¹⁶ University of Massachusetts, Worcester, Massachusetts, USA.
¹⁷ Dartmouth Cancer Center, Lebanon, New Hampshire, USA.
¹⁸ Tufts Medical Center, Boston, Massachusetts, USA.
¹⁹ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
²⁰ Stanford Cancer Institute, Stanford University, Stanford, California, USA.
²¹ University of Pennsylvania, Philadelphia, Pennsylvania, USA.
²² Lowell General Hospital, Lowell, Massachusetts, USA.
²³ Analysis Group Inc., Montreal, Quebec, Canada.

PMID: 39698781
PMCID: PMC11803543
DOI: 10.1002/ajh.27563

Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Nilanjan Ghosh et al. Am J Hematol. 2025 Mar.

. 2025 Mar;100(3):511-515.

doi: 10.1002/ajh.27563. Epub 2024 Dec 19.

Authors

Affiliations

¹ Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, North Carolina, USA.
² Churchill Hospital, Oxford University, Oxford, UK.
³ Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
⁴ Columbia University, New York, New York, USA.
⁵ AbbVie Inc., North Chicago, Illinois, USA.
⁶ University of California Irvine, Irvine, California, USA.
⁷ Fred Hutchinson Cancer Research Center, Seattle, Washington State, USA.
⁸ John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, USA.
⁹ CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
¹⁰ Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
¹¹ Lymphoma and CLL Program, Novant Health Cancer Institute, Charlotte, North Carolina, USA.
¹² Hôpital Maisonneuve-Rosemont, University of Montreal, Canada.
¹³ Cleveland Clinic, Cleveland, Ohio, USA.
¹⁴ Nottingham University Hospitals, NHS Trust, Nottingham, UK.
¹⁵ Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.
¹⁶ University of Massachusetts, Worcester, Massachusetts, USA.
¹⁷ Dartmouth Cancer Center, Lebanon, New Hampshire, USA.
¹⁸ Tufts Medical Center, Boston, Massachusetts, USA.
¹⁹ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
²⁰ Stanford Cancer Institute, Stanford University, Stanford, California, USA.
²¹ University of Pennsylvania, Philadelphia, Pennsylvania, USA.
²² Lowell General Hospital, Lowell, Massachusetts, USA.
²³ Analysis Group Inc., Montreal, Quebec, Canada.

PMID: 39698781
PMCID: PMC11803543
DOI: 10.1002/ajh.27563

No abstract available

Keywords: Bruton tyrosine kinase inhibitor; chronic lymphocytic leukemia; real‐world outcomes; venetoclax.

PubMed Disclaimer

Conflict of interest statement

NG has received consulting fees from AbbVie, AstraZeneca, Janssen, Bristol Myers Squibb, Gilead Sciences/Kite Pharma, Beigene, Incyte, Roche/Genentech, Novartis, Loxo Oncology, Genmab, ADC Therapeutics and Ascentage Pharma; he has received research funding from Genentech/Roche, Bristol Myers Squibb, Gilead Sciences/Kite Pharma, Incyte, AstraZenca, AbbVie. NL: Advisory board member/consulting for Abbvie, BeiGene, EliLilly/Loxo, Genmab, Janssen, Pharmacyclics, Gilead, AstraZeneca; Institutional Research Funding: AbbVie, AstraZeneca, Eli Lilly/Loxo, Genentech, Genmab, Bei‐Gene, MingSight, Oncternal, Octapharma. TAE: Roche: Education Honorarium, Advisory Board Honorarium, Travel support; Gilead: Honorarium; Research support; travel to scientific conferences; KITE: Advisory Board Honorarium; Janssen: Honorarium; Abbvie: Honorarium; travel to scientific conferences; AstraZeneca: Honorarium, Research funding; Loxo Oncology: Advisory Board Honorarium, Trial steering committee; Beigene: Advisory Board Honorarium, Research funding; Incyte: Advisory Board Honorarium; Secura Bio: Advisory Board Honorarium. CCC: Received honoraria/consulted for AbbVie, Allogene, AstraZeneca, Beigene, Genentech, Janssen, LOXO/Lilly, MEI Pharma, Mingsight, Octapharma, TG Therapeutics; Speaker's Bureau: AbbVie, AstraZeneca, Beigene, Genentech; Received research funding (paid to the institution) from AbbVie, AstraZeneca, Beigene, CarnaBio, LOXO/Lilly. BSM, NE, DJ, WS: employees of AbbVie and may hold stock or stock options. SEM: retired from AbbVie. JRB: Consultancy: Abbvie, Acerta/Astra‐Zeneca, Alloplex Biotherapeutics, BeiGene, Galapagos NV, Genentech/Roche, Grifols Worldwide Operations, InnoCare Pharma Inc. iOnctura, Kite, Loxo/Lilly, Merck, Numab Therapeutics, Pfizer, Pharmacyclics; Research funding: BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, TG Therapeutics. HHT: Consultancy: Abbvie; Advisory Board: EliLilly/LOXO and Astrazeneca CU: Honorarium—Abbvie, Astrazeneca, Beigene, Genentech, Jansen, Lilly, Pharmacyclics; Research funding—AbbVie, Astrazeneca, Lilly, PCYC. LAL: Kite/Gilead, Beigene, Pharmacyclics, Abbvie, Genmab, SeaGen, Janssen, AstraZeneca, Eli Lily, Epizyme. Consultant/ad board: ADC Therapeutics, Kite/Gilead, Beigene, Pharmacyclics, Abbvie, Genmab, SeaGen, Janssen, AstraZeneca, Eli Lily, Epizyme, Merck. LER: Consultant for AbbVie, Ascentage, AstraZeneca, Beigene, Janssen, Loxo Oncology, Pharmacyclics, Pfizer, TG Therapeutics, is a member of a data safety monitoring committee (DSMC) for Ascentage, served as a CME speaker for DAVA, Curio, Medscape, and PeerView, holds minority ownership interest in Abbott Laboratories, received travel support from LOXO oncology, and has received research funding (paid to the institution) from Adaptive Biotechnologies, AstraZeneca, Genentech, AbbVie, Pfizer, Loxo Oncology, Aptose Biosciences, Dren Bio, and Qilu Puget Sound Biotherapeutics. LER is also supported in part by National Institutes of Health/National Cancer Institute Cancer Center support grant P30 CA008748. MSD: received research funding from AbbVie, AstraZeneca, Ascentage Pharma, Genentech, Novartis, Surface Oncology; and consulting fees from AbbVie, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, BeiGene, BMS, Eli Lilly, Genentech, Genmab, Janssen, Merck, Mingsight Pharmaceuticals, Nuvalent, ONO Pharmaceuticals, Secura Bio, TG Therapeutics, Takeda. JMR: Consultancy: Abbvie, AstraZeneca, ADC Therapeutics, Beigene, Epizyme, Genentech, GenMab, Loxo Oncology, Janssen, Morphosys, Pharmacyclics, Pfizer Membership on a Board or Advisory Committee: Abbvie, Beigene, Janssen, Research Funding: Acerta, Beigene, Epizyme, Janssen, Loxo Oncology, Oncternal, Pharmacyclics, Velosbios. APS: Research support: AbbVie, Pharmacyclics, Verastem, Acerta Pharma, AstraZeneca, Celgene, Kite Pharma, and Bristol‐Myers Squibb; Honoraria: AbbVie, Pharmacyclics, Genentech, Seattle Genetics, Novartis, Verastem, Jazz Pharmaceuticals, AstraZeneca, Celgene, Kite Pharma, BeiGene, Gilead Sciences; Consultancy: AbbVie, Pharmacyclics, AstraZeneca, Kite Pharma, Celgene, Genentech, Jazz Pharmaceuticals, Alexion; Speaker and consulting fees: Lilly, ADC Therapeutics. IF: Consultant and/or Advisory board: Abbvie, Astrazeneca, Beigene, Bristol Myers Squibb, Gilead, Incyte Janssen, Merck, Novartis, Roche, Seattle Genetics. BTH: Advisory boards for Genentech, AbbVie, Pharmacyclics, Gilead. Research funding: Genentech, AbbVie, Pharmacyclics. NM: Speaker and travel support: AbbVie, AstraZeneca, Janssen; Advisory Boards: AbbVie, AstraZeneca, BeiGene, Takeda. PMB: Consultancy for AbbVie; Research funding: Astrazeneca, TG therapeutics; consulting for AstraZeneca, TG, Pharmacyclics, Celgene, Genentech, Morphosys, Seattle Genetics, MEI, Gilead, Janssen. LP: Nothing to disclose. FL: Nothing to disclose. YC: Nothing to disclose. CEJ: Consultancy: AbbVie. SJS: Consultant and Institutional Research Funding: Novartis, Pharmacyclics, Celgene; Institutional Research Funding: Gilead, Janssen Research & Development, Merck; Scientific Advisory Committees: Nordic Nanovector; Consultant: Genentech, Acerta. IP, TW, and AG are employees of Analysis Group Inc. which has received consultancy fees from AbbVie. BF: Consultancy and Advisory Board: AbbVie, ADC therapeutics, AstraZeneca, BeiGene, BMS, Eli Lilly, Genentech, Genmab, Pharmacyclics; Research funding: AbbVie/Genmab, Loxo‐Lilly, BMS, Angiocrine. Speaker Bureau: Loxo/Lilly. MS: Consulting, advisory boards, steering committees or data safety monitoring committees: Abbvie, Genentech, AstraZeneca, Genmab, Janssen, Beigene, Bristol Myers Squibb, Morphosys/Incyte, Kite Pharma, Eli Lilly, Mustang Bio, Fate therapeutics, Nurix and Merck; institutional research funding from Mustang Bio, Genentech, AbbVie, Beigene, AstraZeneca, Genmab, Morphosys/Incyte, and Vincerx; Stock options: Koi Biotherapeutics; Employment: Bristol Myers Squibb (spouse). DMS: has received consulting fees from Abbvie, AstraZeneca, Beigene, BMS, Celegene, Eli Lilly, Genentech, Janssen, Pharmacyclics. My institution has received clinical research grants from AstraZeneca, Novartis, BMS. MC: Nothing to disclose.

References

1. Patel K. and Pagel J. M., “Current and Future Treatment Strategies in Chronic Lymphocytic Leukemia,” Journal of Hematology & Oncology 14, no. 1 (2021): 69. - PMC - PubMed
1. Thompson M. C. and Mato A. R., “Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors,” Hematology/Oncology Clinics of North America 35, no. 4 (2021): 793–806. - PubMed
1. Eyre T. A., Kirkwood A. A., Gohill S., et al., “Efficacy of Venetoclax Monotherapy in Patients With Relapsed Chronic Lymphocytic Leukaemia in the Post‐BCR Inhibitor Setting: A UK Wide Analysis,” British Journal of Haematology 185, no. 4 (2019): 656–669. - PubMed
1. Sobon A., Drozd‐Sokolowska J., Paszkiewicz‐Kozik E., et al., “Clinical Efficacy and Tolerability of Venetoclax Plus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia‐a Real‐World Analysis of the Polish Adult Leukemia Study Group,” Annals of Hematology 102, no. 8 (2023): 2119–2126. - PMC - PubMed
1. Lew T. E., Bennett R., Lin V. S., et al., “Venetoclax‐Rituximab Is Active in Patients With BTKi‐Exposed CLL, but Durable Treatment‐Free Remissions Are Uncommon,” Blood Advances 8, no. 6 (2024): 1439–1443. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Affiliations

Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Authors

Affiliations

Conflict of interest statement

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources